Patients get printed drug safety info with every prescription—manufacturers bear the cost

What it does

This bill requires pharmaceutical manufacturers to include a standardized, single-page printed patient medication information sheet with every prescription drug dispensed in non-hospital settings. The FDA must issue regulations within one year specifying the format, content, language, graphics, and distribution requirements. The sheet must include drug name, indications, directions, contraindications, warnings, adverse reactions, interactions, storage/disposal instructions, manufacturer contact info, and a link to report adverse events. Failure to include this printed information would constitute misbranding.

Why we flagged it

The bill's operative mechanism is a mandatory disclosure requirement—manufacturers must provide standardized printed patient information with every prescription. This is a consumer-protection and public-health measure, not a tax provision, subsidy, or deregulation. The character is straightforward patient safety.

What the text implies

• Manufacturers may face significant printing and packaging costs, which could be passed to insurers, pharmacy benefit managers, or patients through higher drug prices or copays, offsetting some of the bill's cost-savings claims.
• The bill requires FDA to develop regulations within one year; if the agency lacks resources or prioritizes other rulemakings, implementation delays could push the effective date well beyond the statutory deadline.
• Standardized format requirements may create compliance challenges for drugs with complex or numerous adverse reactions, potentially leading to font-size or content-compression disputes with the FDA.
• The bill does not address how printed information will be distributed in mail-order or online pharmacy settings, creating potential gaps in compliance for a growing segment of prescription fulfillment.
• Manufacturers may face liability exposure if printed information is deemed inadequate or if adverse events occur despite compliance, potentially triggering litigation over the adequacy of the FDA-approved format.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients gain direct access to standardized, plain-language drug safety information in printed form, addressing a documented gap for those without electronic access and reducing preventable adverse drug events. The bill's findings cite $14.6–$26.2 billion in potential annual savings from reduced emergency room visits and hospitalizations, though this is a secondary benefit; the primary civic gain is informed patient decision-making and safer medication use.

Who stands to gain

• printing and packaging service providers
• pharmaceutical manufacturers (regulatory clarity and safe harbor from certain liability claims)
• pharmacy benefit managers and insurers (potential long-term savings from reduced adverse events)

Named in the bill

FDA (Food and Drug Administration), Centers for Disease Control and Prevention (CDC), Government Accountability Office (GAO), pharmaceutical manufacturers, pharmacies, patients, Federal Food, Drug, and Cosmetic Act, Form FDA 3500B

Where it stands

12 cosponsors: 7 Democrats, 5 Republicans.

• Sep 4, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 4, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

3 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $440,000 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 61% of bills with at least one filing.

Cliff Bentz, the sponsor, reported $618,750 in PAC receipts in the 2026 cycle.

• National Community Pharmacists Association — $270,000 on 1 filing
• Xerox Holdings Corporation — $120,000 on 2 filings
• Printing United Alliance — $50,000 on 1 filing

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.